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Abstract
Genetic causes for autosomal recessive forms of dilated cardiomyopathy (DCM) are only rarely identified, although they are
thought to contribute considerably to sudden cardiac death and heart failure, especially in young children. Here, we
describe 11 young patients (5–13 years) with a predominant presentation of dilated cardiomyopathy (DCM). Metabolic
investigations showed deficient protein N-glycosylation, leading to a diagnosis of Congenital Disorders of Glycosylation
(CDG). Homozygosity mapping in the consanguineous families showed a locus with two known genes in the N-
glycosylation pathway. In all individuals, pathogenic mutations were identified in DOLK, encoding the dolichol kinase
responsible for formation of dolichol-phosphate. Enzyme analysis in patients’ fibroblasts confirmed a dolichol kinase
deficiency in all families. In comparison with the generally multisystem presentation in CDG, the nonsyndromic DCM in
several individuals was remarkable. Investigation of other dolichol-phosphate dependent glycosylation pathways in
biopsied heart tissue indicated reduced O-mannosylation of alpha-dystroglycan with concomitant functional loss of its
laminin-binding capacity, which has been linked to DCM. We thus identified a combined deficiency of protein N-
glycosylation and alpha-dystroglycan O-mannosylation in patients with nonsyndromic DCM due to autosomal recessive
DOLK mutations.
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Introduction
Dilated cardiomyopathy (DCM) is a life-threatening disease
characterized by left ventricular enlargement and systolic
dysfunction, which can lead to congestive heart failure and is a
common cause of patients requiring heart transplantation. In view
of the progressive disease course and the acuteness of presenting
symptoms, early recognition and diagnosis of the underlying
etiology is essential. Genetic causes for DCM are estimated to
explain 20–48% of all idiopathic patients [1–3]. Until now, 33
nonsyndromic DCM genes have been identified, two on the X
chromosome and 31 on the autosomes, of which only one shows
recessive inheritance [4]. We expect more recessive genes, since
recessive forms have been shown to explain up to 16% of familial
DCM [5]. Especially in young children (,10 years old) these are
expected to contribute considerably to disease [6].
Protein N-glycosylation is a very common co-translational
modification of many proteins, following a sequential and highly
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and Golgi apparatus. Genetic defects in this pathway generally
lead to a multisystem disease. These inborn errors of metabolism
form the group of Congenital Disorders of Glycosylation (CDG)
for which currently more than 40 different genetic defects are
known [7]. Defects in the ER during the assembly of the lipid-
linked oligosaccharide [8], and glycan transfer to nascent protein
chains affect all N-linked proteins and typically lead to a
multisystem presentation in CDG-I patients. Clinically such
patients are characterized by psychomotor and intellectual
disability, muscle hypotonia, seizures, ophthalmologic anomalies,
failure to thrive, endocrine and coagulation abnormalities and
variable dysmorphic features. Dilated cardiomyopathy in CDG is
very rare and has only been described in one of the two reported
families with dolichol kinase deficiency (DOLK-CDG, MIM
610768) as part of a multisystem presentation with profound
muscular hypotonia, ichthyosiform skin, nystagmus, epilepsy and
pulmonary infections, leading to death within the first months of
life [9], and in patients with liver involvement [10] or cognitive
delay [11]. On the other hand, cardiomyopathy of the
hypertrophic type is common in CDG type I [12–14]; it is one
of the lethal comorbidity factors in CDG-Ia (PMM2-CDG, MIM
212065) patients in infancy.
In this paper, we present eleven young patients (age 5–13 years)
with CDG and recessive mutations in DOLK with a predominantly
nonsyndromic presentation of DCM. In addition, we show that
the main presenting symptom of DOLK-CDG is caused by
deficient O-mannosylation of sarcolemmal alpha-dystroglycan.
Results
Clinical presentation of dilated cardiomyopathy
Dilated cardiomyopathy was diagnosed in several children (see
pedigree; Figure 1), without significant muscular weakness or
creatine kinase (CK) elevation. Central nervous system involve-
ment, such as cerebellar ataxia, epilepsy or intellectual disability
was not present in the patients, except for transient muscular
hypotonia and mild developmental delay with a minor increase of
CK in family IV. Decreased coagulation parameters were
observed in all individuals.
Family I
Patient I/2, the second male child of healthy, consanguineous
parents of Druze origin was referred to the pediatric metabolic
unit for evaluation of mild failure to thrive and persistent elevated
transaminases during infancy. Impaired glycosylation (CDG-I) was
diagnosed at the age of 10 months [15]. At 6 years of age a mild
asymptomatic dilatation of the left ventricle was shown on
echocardiogram. He developed acute heart failure at age 11.
Patient I/3, the younger brother of patient I/2, is clinically
asymptomatic. At age 4 years, following the diagnosis of his
brother, mildly elevated transaminases were noticed. He under-
went echocardiography, which revealed mild dilated cardiomyop-
athy.
Family II
Patient II/2, the second male child of healthy, consanguineous
parents of Druze origin, was clinically healthy until the age of 9
years, when he was admitted with acute congestive heart failure
and dilated cardiomyopathy of unknown etiology. He died
suddenly following heart arrhythmia.
Patient II/5, sister of patient II/2, was diagnosed with a dilated
cardiomyopathy at age 7. Biopsied ventricles of the explanted
heart revealed myocyte hypertrophy and interstitial fibrosis
(Figure 2), more pronounced in the left ventricle than in the right
ventricle.
Patient II/6, a younger sister of patient II/5, had a history of
mild hypotonia, failure to thrive, short stature and ichthyosiform
dermatitis. She was diagnosed with mild dilated cardiomyopathy
at the age of 6 years.
Family III
Patient III/2 was the second male child of healthy, consanguin-
eous parents of Beduin origin. At age 9 years, he presented with
progressive weakness over the last month. These symptoms led to
the diagnosis of ‘‘viral myocarditis’’ resulting in an end-stage
dilated cardiomyopathy and death after unsuccessful reanimation.
Patient III/1, a 13 years old sister of III/2, was found to have
asymptomatic dilated cardiomyopathy following the diagnosis of
her brother. Her younger brothers, patient III/3 of 11 years old,
and III/4 of 9 years old showed asymptomatic minimal evidence
of cardiomyopathy detected by repeated echocardiograms. On
supportive treatment no further deterioration of the cardiac
function was observed during the 3 years of follow up.
Ichthyosiform dermatitis was noticed in siblings 2, 3 and 4.
Family IV
An 11-year-old female of Indian origin with a background of
learning difficulties, mild hypotonia and ichthyosis, presented with
cardiac failure secondary to severe dilated cardiomyopathy. Prior
to the diagnosis of CDG, her condition deteriorated; she required
mechanical support and was listed for cardiac transplant. She died
of thrombotic and septic complication whilst having Berlin heart
as bridging procedure for transplant. Her younger brother was
diagnosed with the same defect. He has mild developmental delay
but cardiac function is normal.
Glycosylation studies
Transferrin isoelectric focusing for analysis of N-glycosylation
abnormalities was performed during metabolic screening. Con-
vincingly abnormal profiles were found for all affected patients,
Author Summary
Idiopathic dilated cardiomyopathy (DCM) is estimated to
be of genetic origin in 20%–48% of the patients. Almost all
currently known genetic defects show dominant inheri-
tance, although especially in younger children recessive
causes have been proposed to contribute considerably to
DCM. Knowledge of the genetic causes and pathophysi-
ological mechanisms is essential for prognosis and
treatment. Here, we studied several individual young
patients (5–13 years old) with idiopathic and sometimes
asymptomatic dilated cardiomyopathy. The key to identi-
fication of the gene was the finding of abnormal protein N-
glycosylation. Via homozygosity mapping and functional
knowledge of the N-glycosylation pathway, the causative
gene could be identified as dolichol kinase (DOLK). Since
DCM is very rare in N-glycosylation disorders (Congenital
Disorders of Glycosylation, CDG) and most patients with
CDG present with a multisystem involvement, we studied
the underlying pathophysiological cause of this life-
threatening disease. Biochemical experiments in affected
heart tissue showed deficient O-mannosylation of alpha-
dystroglycan, which could be correlated with the dilated
cardiomyopathy. Our results thus highlight nonsyndromic
DCM as a novel presentation of DOLK-CDG, via deficient O-
mannosylation of alpha-dystroglycan.
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PLoS Genetics | www.plosgenetics.org 2 December 2011 | Volume 7 | Issue 12 | e1002427Figure 1. Pedigrees, haplotypes, and mutation analysis of families I through IV. Upper panels: segregation analysis of the homozygous
region at 9q33.1-qter. Black bars represent haplotypes that segregate with the disease. Lower panels: chromatograms of affected family members
showing the c.1222C.G, c.912G.T, and c.3G.A mutations (upper profile) and of controls (lower profile). Mutated base pairs and corresponding
amino acid residues are printed in bold.
doi:10.1371/journal.pgen.1002427.g001
Figure 2. Histology and immunohistochemistry of heart sections of patient II/5 stained with haematoxylin eosin (HE), alpha
dystroglycan clone IIH6C4 (IIH6), beta dystroglycan (b-dys), beta-sarcoglycan (b-sar), and desmin. PR: right ventricle of patient, PL: left
ventricle of patient, C: control. Bar=0.05 mm.
doi:10.1371/journal.pgen.1002427.g002
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decreased tetrasialotransferrin (Figure 3). These results indicated a
diagnosis of CDG type I with a genetic defect in the cytoplasm or
endoplasmic reticulum. The most common subtype PMM2-CDG
(CDG-Ia) was excluded by analysis of phosphomannomutase
activity in patient fibroblasts. In view of the specific clinical
symptoms and consanguinity in families I and II, we chose a direct
homozygosity mapping approach instead of lipid-linked oligosac-
charide analysis.
Homozygosity mapping
Homozygosity mapping was performed in two Israeli families (I
and II, Figure 1) using the Affymetrix GeneChip Mapping 10 K
2.0 array (family I) and the Affymetrix GeneChip Human
Mapping 250 k NspI Array (family II). The largest overlapping
homozygous region in families I and II was found on chromosome
9. In family I, the 19.1 Mb region at 9q33.1–9q34.3 was delimited
by SNP_A-1518745 and 9pter. By using the two siblings of family
II, the overlapping region could be confined to 5.0 Mb at 9q33.3
and 9q34.11, delimited by SNP_A-4223282 and SNP_A-2111464.
Short tandem repeat (STR) marker analysis confirmed homozy-
gosity of this region and showed that the haplotypes of the two
Israeli families were identical (Figure 1, I and II). The three
affected siblings of family III with a similar phenotype were
homozygous for the same region, delimited by D9S1872 and
9qter. The overlapping homozygous region of the three families
contained 117 genes. Comparison of this region with a list of
candidate genes for CDG-I glycosylation defects highlighted two
candidate genes known to be involved in protein N-glycosylation,
DOLPP1 and DOLK.
Mutation analysis
Analysis of the protein coding sequence of DOLK in family I
showed a homozygous missense mutation (c.1222C.G; p.Hi-
s408Asp; Figure 1A). The same mutation was identified in family
II. The finding in two seemingly unrelated kindreds, who reside
in two different villages in Northern Israel, and the presence of
an identical 5 Mb interval haplotype including the same
mutation, suggest a founder event among these Druze kindreds.
In family III, a homozygous c.912G.T transition was identified
resulting in a p.Trp304Cys amino acid change. Both His408 and
Trp304 are fully conserved down to zebrafish (Figure S1) and
both SIFT [16] and PolyPhen [17] programs predict these
changes to be damaging for protein function. On basis of a
similar clinical presentation, DOLK was sequenced in DNA of
family IV. A third homozygous mutation (c.3G.A, Figure 1D)
Figure 3. CDG biochemistry. A. N-glycosylation abnormalities in affected patients as observed by isoelectrofocusing of serum transferrin. 0, 2 and
4 indicate asialo-, disialo-, and tetrasialotransferrin isoforms. C: control, PMM2: PMM2-CDG. B. Dolichol kinase activity in patient (n=5) and control
(n=7) fibroblasts. Microsomal fractions were incubated with c
32P-CTP and dolichol-19, and dolichol-
32P production was measured.
doi:10.1371/journal.pgen.1002427.g003
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(p.Met1Ile), which is conserved from human to zebrafish. All
three mutations were not present in .1000 healthy Caucasian
controls as shown by high resolution melting analysis, by exome
sequencing, and by using data from the 1000 genomes project
(www.1000genomes.com) (Text S1). Analysis of the protein
coding sequence of DOLPP1 in families I and II did not show any
sequence variations.
Analysis of CTP–dependent dolichol kinase activity
Activity of dolichol kinase was assessed in patient fibroblast
homogenates using dolichol-19 as acceptor and c
32P- cytidine 59-
triphosphate (CTP) as phosphate donor. Analysis of
32P
incorporation into dolichol-P clearly showed strongly reduced
enzyme activity for five patients of all four families investigated
(Figure 3B). Fibroblasts from CDG-I patients with a different
genetic defect showed dolichol kinase activity comparable to
controls.
Functional analysis of DOLK mutant alleles in the
temperature sensitive yeast sec59 mutant
SEC59 is the yeast ortholog of DOLK [18]. A sec59 yeast mutant
that displays temperature sensitive lethality as well as an
underglycosylation of glycoproteins at the restrictive temperature
was used to further confirm the non-functionality of the
mutations in our patients. In addition, we have compared the
novel mutations with the previously reported mutations in the
two DOLK-CDG patients. All strains showed comparable
growth at the permissive temperatures of 25 or 32uC, whereas
at the restrictive temperature of 37uC only wild-type DOLK
supported growth (Figure 4A). N-glycosylation of the same
mutant alleles was assessed by western blotting of the vacuolar
glycoprotein carboxypeptidase Y (CPY), containing four N-
glycan chains (Figure 4B). At the restrictive temperature CPY is
underglycosylated in sec59 cells, visualized by the appearance of
glycoforms lacking one to four N-glycan chains. Consistent with
the cell growth results, wild-type DOLK was able to restore the
glycosylation of CPY at 37uC, as evidenced by a shift to the more
mature forms of CPY and a decrease of underglycosylated
isoforms. All mutants failed to restore glycosylation to the same
extent as wild-type DOLK. The p.Tyr441Ser and p.Cys99Ser
mutants showed no or marginal improvement, respectively, as
compared to sec59 cells. The three new mutants, however,
improved the glycosylation to a higher extent as the glycosylation
patterns showed a more prominent band of CPY with two N-
glycans as compared to CPY with only one N-glycan.
Figure 4. Functional analysis of DOLK mutant alleles in the temperature sensitive yeast sec59 mutant. A. Serial dilutions of sec59 mutant,
transformed with plasmids, harboring either wild-type DOLK, mutant alleles, or empty vector, were plated on YPD media and incubated at 25, 32, or
37uC. B. Glycosylation pattern of CPY in sec59 mutant transformed with wild-type and mutant DOLK alleles. Cells were cultivated at the permissive
temperature of 25uC and shifted for 10 h to 32 or 37uC, followed by immunoblotting as described [19]. The positions of mature CPY (mCPY) and
underglycosylated forms lacking one to four N-glycans are indicated.
doi:10.1371/journal.pgen.1002427.g004
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expression
To explain the tissue-restricted clinical phenotype in our patient
group, we performed expression analysis of DOLK in fetal and
adult tissue and biochemical analysis of the dolichol-phosphate
dependent N-glycosylation and O-mannosylation. Highest expres-
sion levels of DOLK mRNA were found in fetal and adult brain,
followed by skeletal muscle and heart in fetal tissue and heart in
adult (Figure 5).
Dolichol-P is required for N-glycosylation in the ER. In
addition, dolichol-P is converted to dolichol-P-mannose, the
monosaccharide donor for N-glycosylation inside the ER lumen
and for O-mannosylation of alpha-dystroglycan. O-mannosyla-
tion was assessed by direct immunofluorescence staining of a
frozen heart biopsy with the IIH6 antibody directed against the
O-mannosyl glycans of alpha-dystroglycan. Reduced and/or
fragmented staining was observed, more pronounced in the right
ventricle. The intensity of the sarcolemmal proteins beta-
dystroglycan and beta-sarcoglycan was normal, while the
intensity of intracellular desmin was somewhat increased
(Figure 2). Western blotting was performed on heart muscle
homogenates. IIH6 staining of WGA-enriched fractions was
reduced (Figure 6A), which was confirmed in the laminin-overlay
(LO) assay showing a reduction of the laminin-binding capacity of
alpha-dystroglycan. To correct for muscle specific staining,
western blotting was performed on non-enriched heart homog-
enates (Figure 6A) using anti-desmin and anti-b-sarcoglycan
primary antibodies. Equal signals were observed for control and
patient materials. However, the laminin-overlay assay clearly
showed a reduction in signal intensity, similar to the results in
WGA-enriched fractions. Additional control studies were per-
formed in heart tissues of patients with idiopathic cardiomyop-
athy (Figure 6A, PC), with similar results as for the healthy
controls (HC). N-glycosylation was analyzed by western blotting
of the lysosomal glycoprotein CD63 (LAMP3). In fibroblasts of a
DPM1-CDG patient, a clear shift was seen to a lower
glycosylated CD63 isoform, indicating aberrant N-glycosylation
of CD63 as compared to control fibroblasts. Glycosylation of
CD63 in dolichol kinase deficient fibroblasts was comparable to
controls (Figure 6B). Analysis of homogenized heart tissue showed
a shift in CD63 isoforms in dolichol kinase deficient heart
material as compared to control heart, indicating reduced N-
glycosylation.
Figure 5. Expression of dolichol kinase by mRNA expression analysis in human fetal and adult tissues. Relative expression levels are
given as the fold change in comparison to the tissue with the lowest expression level.
doi:10.1371/journal.pgen.1002427.g005
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In a cohort of 11 patients, presenting primarily with
nonsyndromic dilated cardiomyopathy at the age of 5–13 years,
we identified three separate mutations in DOLK as the underlying
cause of disease. Some of the patients showed mild additional
clinical symptoms, such as ichthyosis, failure to thrive and mild
neurological involvement. In contrast, the two families with DOLK
mutations originally described by Kranz et al [9] showed a severe
congenital multisystem phenotype including a variable presenta-
tion of cardiac failure, severe muscular hypotonia, and ichthyosis,
with epilepsy due to hypsarrhythmia, microcephaly and visual
impairment, leading to death within 6 months after birth. Dolichol
kinase is an endoplasmic reticulum resident protein with a
cytidine-59-triphosphate (CTP) binding pocket in the C-terminal
domain that is exposed to the cytoplasmic face [20]. The exact
catalytic mechanism, the hydrophobic binding sites for dolichol,
and a possible role in dolichol-P recycling have not been clarified
as yet. Our and the previously identified mutations occur in or
near transmembrane domains, not associated with a specific
function (Figure S1). Functional investigation of these mutant
alleles in the temperature sensitive yeast strain sec59, deficient in
dolichol kinase activity, showed sustained reduced growth at 37uC.
Moreover, a less severe underglycosylation of CPY was found in
the three new mutants as compared to the two mutations from the
previous report, which is in agreement with the milder clinical
phenotype in our families.
DOLK mutations result in abnormal N-glycosylation as
determined by analysis of serum transferrin glycosylation in our
patients. Remarkably, only minor classical symptoms of CDG-I
could be identified in the patients described here, such as
increased liver transaminases in some and a slight decrease in
coagulation parameters in all patients. No signs of cerebellar
hypoplasia were observed, as commonly seen in the most
frequent CDG subtype PMM2-CDG. On the other hand, dilated
cardiomyopathy is uncommon in CDG patients with an N-
glycosylation defect. A single case out of more than 40 known
ALG6-CDG (MIM 603147) patients was reported with a
multisystem presentation including DCM [21]. In DPM3-CDG
(MIM 612937), DCM was reported as minor symptom compared
to the muscular dystrophy [22]. As deduced from deficient IIH6
staining in skeletal muscle, both clinical symptoms were linked to
deficient O-mannosylation of alpha-dystroglycan. In the disorders
of dystroglycan O-mannosylation, a subgroup of the congenital
muscular dystrophies, DCM is commonly observed in combina-
tion with limb-girdle muscular dystrophy at the milder end of the
spectrum. Patients with dilated cardiomyopathy and no or
minimal muscle involvement were reported with mutations in
Figure 6. Western blotting for analysis of O-mannosylation and N-glycosylation. O-mannosylation (A) and N-glycosylation (B). A. Heart
muscle homogenates were used with (left panel) or without (right panel) WGA-enrichment and stained for desmin, b-dystroglycan, b-sarcoglyan,
glycosylated a-dystroglycan (IIH6) and used for functional analysis of laminin binding. PR: patient II/5 right ventricle; PL: patient II/5 left ventricle; HC:
healthy control; PC: pathological cardiomyopathy control. B. Patient and control fibroblasts and heart tissue homogenates were used for western
blotting of CD63. Lanes 1 and 4: control; lane 2: DPM1-CDG; lane 3: DOLK-CDG; lane 5: patient right ventricle; lane 6: patient left ventricle.
doi:10.1371/journal.pgen.1002427.g006
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showing reduced laminin binding capacity of alpha-dystroglycan
in heart muscle biopsies. The involvement of dystroglycan O-
mannosylation in the phenotype of our cohort of dolichol kinase
deficient patients was shown by reduced IIH6 staining in frozen
heart biopsy material. Western blot analysis showed a reduction
in the laminin binding capacity of alpha-dystroglycan, thereby
confirming a loss of alpha-dystroglycan function. Recently, the
loss of functional alpha-dystroglycan as extracellular receptor in
cardiac myocytes was shown to be the cause of dilated
cardiomyopathy in mutant mice [25]. Dystroglycan was postu-
lated as an important extracellular matrix receptor to limit the
damage of cardiomyocyte membranes after exercise-induced
stress to individual cells.
O-Mannosylation of alpha-dystroglycan (Figure 7) involves the
protein O-mannosyltransferases POMT1 and POMT2 and the
GlcNAc transferase POMGnT1. In addition fukutin, fukutin-
related protein and LARGE have been shown to be involved in
O-mannosylation, where LARGE is involved in a phosphoryla-
tion process of the O-mannosyl glycan [26]. Defects in these six
genes have been described as cause for the dystroglycanopathies
[27], explaining disease in only about 50% of the patients [28].
Defects in the biosynthetic genes of the sugar donor dolichol-P-
mannose required for the O-mannosylation process, like DPM3
[22] and likely DPM1 [29,30], result in abnormal dystroglycan
O-mannosylation. Here, we show that mutations in dolichol
kinase also lead to reduced dystroglycan O-mannosylation, likely
via reduced availability of dolichol-P-mannose. This is supported
by previous studies in yeast cells [31]: amphomycin, which binds
to and inhibits the use of dolichol-phosphate, was shown to
reduce the production of dolichol-P-mannose with a subsequent
reduction of protein O-mannosylation. Interestingly, N-glycosyl-
ation of the O-mannosylating enzymes POMT1 and POMT2
was shown to be required for their activity [32]. This implies that
in dolichol kinase deficiency, O-mannosylation could be reduced
via two independent mechanisms, i.e. via reduced availability of
dolichol-P-mannose and via reduced activity of O-mannosyla-
tion enzymes due to deficient N-glycosylation. Possibly, this leads
to increased susceptibility of the O-mannosylation pathway in
defects of dolichol-P or dolichol-P-mannose synthesis. In
contrast, the clinical phenotype of CDG-If (MPDU1-CDG,
MIM 609180) does not include muscular dystrophy or dilated
cardiomyopathy in spite of the reduced availability of dolichol-P-
m a n n o s ei nt h eE Rl u m e ni nt h i sd i s e a s e[ 3 3 , 3 4 ] .A l s o ,t h e
recently described polyprenol reductase SRD5A3-CDG (MIM
612379) does not show signs of a congenital muscular dystrophy
[35,36]. Apparently, additional factors play a role in determining
the clinical outcome in deficiencies of dolichol-P-mannose
synthesis or utilization. For SRD5A3, a by-pass synthesis route
for dolichol was postulated [35], while both dolichol and
dolichol-phosphate could have a function on their own in
organelle membrane fluidity [37]. Clearly, many factors in
dolichol and dolichol-phosphate homeostasis remain to be
discovered [38], which could differentially affect the clinical
outcome in dolichol cycle defects.
In conclusion, we have shown that dolichol kinase deficiency
results in abnormal N-glycosylation and reduced O-mannosyla-
tion of alpha-dystroglycan, leading to a clinical phenotype of
dilated cardiomyopathy. This new entity of cardiomyopathy
warrants screening for glycosylation defects in any patient with
idiopathic DCM. Dolichol kinase deficiency may initially
present with mild or asymptomatic DCM which may deterio-
rate, underlining the necessity to follow these young patients
closely.
Methods
Patient description
Three families residing in the Galilee regions of Northern Israel
and one Indian family were clinically and genetically investigated.
Over the past five years, 11 children have been diagnosed as
suffering from an autosomal recessive dilated cardiomyopathy
associated with CDG type I transferrin isoelectric focusing profiles
in serum (see pedigrees in Figure 1). Nine patients and 11 of their
close relatives were included in the study. The study protocol was
approved by the Institutional Ethics Review Committee and by
the National Committee for Genetic Studies of the Israeli Ministry
of Health. Informed consent was obtained from all participants
and their legal guardians.
CDG diagnostics
Transferrin isoelectric focusing was carried out as described
before [39]. The clinical symptoms did not show any indication
for the presence of fructosemia or galactosemia as possible
secondary cause for CDG type I transferrin isoelectric focusing
profiles. A protein polymorphism was excluded by neuraminidase
digestion of the samples and by the normal profiles of both
parents. Phosphomannomutase activity was measured in patient
fibroblasts according to [40]. For analysis of dolichol kinase
activity, fibroblast homogenates were incubated with [c-
32P]cy-
tidine 59-triphosphate and dolichol-19 and the formation of
32P-
dolichol was measured according to [9] and described in detail in
Text S1.
Homozygosity mapping
Genomic DNA was extracted from peripheral blood lympho-
cytes using standard salting out procedures [41]. Genotyping was
performed using the Affymetrix NspI 250 K SNP array. All SNP
array experiments were performed and analyzed according to
manufacturer’s protocols (Affymetrix, Santa Clara, CA, USA).
Homozygosity mapping was performed using PLINK v1.06 [42],
using a homozygous window of 50 SNPs tolerating two
heterozygous SNPs and ten missing SNPs per window.
Mutation analysis
Primer sequences for amplification of the only exon of DOLK
(GenBank ID NM_014908.3) are shown in Table S1. PCR
products were sequenced using the ABI PRISM BigDye
Terminator Cycle Sequencing V2.0 Ready Reaction Kit and
analyzed with the ABI PRISM 3730 DNA analyzer (Applied
Biosystems, Foster City, USA).
Immunohistochemistry and western blotting
Immunohistochemistry was performed by incubation of heart
tissue sections with monoclonal antibodies against alpha-dystro-
glycan, beta-dystroglycan, beta-sarcoglycan or desmin (Text S1).
WGA-enriched and non-enriched heart homogenates were used
for western blotting of CD63, beta-dystroglycan, desmin, beta-
sarcoglycan and alpha-dystroglycan and for the laminin overlay
assay as described ([43] and Text S1).
Expression in yeast
For expression of DOLK, the following strain was used: MATa
sec59 ura3-52. Cells were grown in selective YNB (yeast nitrogen
base) medium (0.67% YNB, 0.5% casamino acids and 2%
glucose) or in YPD medium (1% yeast extract, 2% bacto-peptone
and 2%glucose). For growth on plates 2% agar was added. To
construct the yeast expression plasmids, the DOLK open reading
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High-Fidelity DNA Polymerase, New England Biolabs) from the
chromosomal DNA of patients I-3, III-1, and IV-2 and a healthy
control with primers engineered with HindIII and BamHI
restriction sites at the 59and 39 ends, respectively (Table S1).
For patient IV-2, where the mutation is located within the primer
region, the mutation was introduced in the primer. All four
products were subcloned into the pCR4-TOPO vector (Invitro-
gen, Breda, The Netherlands). The two mutations described
previously by Kranz et al. [9] were introduced in the WT-DOLK
containing plasmid by site-directed mutagenesis. Subsequently,
the WT and mutated forms of DOLK were digested with HindIII/
BamH1 and ligated into the HindIII/BamHI digested vector
pVT100-ZZ, thereby placing DOLK under the control of the
constitutive ADH1 (alcohol dehydrogenase 1) promoter. The
correct sequences were verified by sequencing the entire coding
region of the constructs. Transformation into yeast cells was
carried out using standard techniques [19].
Supporting Information
Figure S1 Amino acid changes. A) Schematic representation of
DOLK including the positions of all mutations identified thus far
(this paper and [9]). Transmembrane domains according to
Haeuptle [10] are represented by the numbered black boxes. B)
Alignment of transmembrane domains 9 and 12 from human
(Homo sapiens), mouse (Mus musculus), chicken (Gallus gallus)
and zebrafish (Danio rerio). The substituted amino acid residues
p.Trp304 and p.His408 are highlighted by the black boxes and
conserved in all four species.
(JPG)
Table S1 Primer sequences of primers used for direct DNA
sequencing, HRM, and QPCR analysis of DOLK
(NM_014908.3). In addition, primers for short tandem repeat
(STR) marker analysis, and for cloning and site-directed
mutagenesis of DOLK are shown. STR primers are given without
their M13 tails. The restriction sites used for cloning are
underlined in the respective primers. Introduced nucleotide
mutations are printed in bold.
(DOC)
Text S1 Details on biochemical and genetic methods.
(DOCX)
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